Isotechnika inc. (T.ISA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isotechnika inc. (T.ISA)

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: teevee who started this subject	10/18/2001 10:08:18 PM
From: teevee	Read Replies (2) of 23

Isotechnica's drug "ISAtx247" appears to be a promising new immune suppressive drug, currently undergoing clinical trials. This drug is enrolled in Phase II trials which involve taking patients off transplant drug cyclosporine and putting them on ISAtx247. This drug will also soon enter Phase II trials to treat Psoriasis and Rheumatoid Arthritis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext